secwatch.observer — SEC 8-K summary
======================================

Issuer:     Outlook Therapeutics, Inc. (OTLK)
CIK:        0001649989
Form:       8-K
Filed at:   2026-08-14T12:00:49+00:00
Accession:  0001104659-26-096478
Event type: earnings
Sentiment:  positive
Materiality: 0.90
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Outlook Therapeutics reports Q3 FY2026 results; FDA-approved LYTENAVA launch planned by end of 2026
--------------------------------------------------------------------------------

- Net loss $20.3M ($0.15/share) vs $20.2M ($0.55/share) YoY; adjusted net loss $10.9M ($0.09/share) vs $15.8M ($0.44/share).
- Cash $11.2M at June 30, 2026; subsequent public offering raised ~$51.1M net from 55.6M shares at $0.99.
- FDA approved LYTENAVA (bevacizumab-vikg) for wet AMD; U.S. launch planned before end of calendar 2026.
- Management sees potential to exceed $500M annual U.S. sales by 2030; HCPCS code application by Oct 1, 2026.
- European expansion: Germany, Austria, UK; Netherlands launch later 2026; Switzerland partner Mediconsult launch 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/0001104659-26-096478-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1649989/000110465926096478/tm2622399d3_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-096478

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer